Navigation Links
ERGONEX Pharma receives Frost & Sullivan's European Orphan Diseases Entrepreneurial Company Award 2009
Date:10/19/2009

Appenzell, Switzerland, October 19, 2009 / b3c newswire / - ERGONEX Pharma received one of the prestigious European Orphan Diseases Entrepreneurial Company Award on the occasion of Frost & Sullivan's '2009 Excellence in Healthcare Awards Banquet,' held in London on 8th October 2009. The highly competitive award was presented to ERGONEX Pharma in recognition of the company's innovative therapeutic concept, its impressive display of technological know-how and targeted vision.

ERGONEX Pharma is focused on the clinical development and commercialisation of Terguride for the treatment of distinct orphan diseases. Terguride is currently being evaluated for the treatment of pulmonary arterial hypertension (PAH) in a Phase II trial in Europe and headline results are expected in 2010.

Dr. Rudolf Reiter, CEO of ERGONEX Pharma comments: "This award comes at an exciting and challenging time for ERGONEX Pharma. I see it as recognition of the vision, the commitment and work of the company, which would not have been possible without the continued support, expertise and out-of-the-box thinking of our partners in the on-going clinical trial. We believe that Terguride has the potential to contribute a new quality to emerging combination therapies for patients, who do not tolerate, have become resistant to or are insufficiently controlled by current treatment options in PAH.

The Frost & Sullivan Healthcare Awards Banquet honours Europe's best healthcare companies for their achievements over the course of this year. Frost & Sullivan's highly competitive awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development.

About Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is a disorder of the blood vessels in the lung, in which the pressure in large blood vessel rises above normal. Walls of the blood vessels are thickened and hardened, becoming less elastic. Hence, the decrease in lumen leads to increases in pressure. Patients with PAH suffer from extreme shortness of breath as the heart struggles to pump against these high pressures causing such patients to ultimately die of heart failure.

About Terguride
Terguride acts as a potent antagonist on 5-HT2B and 5-HT2A receptors: It has anti-proliferative and anti-fibrotic activities and drives reverse remodelling processes. Serotonin is a signal molecule in the body with many functions. In the blood vessel walls of the lung, it stimulates proliferation of smooth muscle cells and narrowing of the blood vessels, which has been implicated in PAH. Furthermore, trophic effects of serotonin on the heart contribute to right heart hypertrophy and progression towards heart failure. Terguride is approved in Japan for hyperprolactinemia acting as a partial dopamine agonist on the pituitary gland.

About ERGONEX Pharma - www.ergonex.com
ERGONEX Pharma is a pharmaceutical company focused on developing and commercialising well-tolerated and effective products for novel and typically underserved indications. This is being achieved by forging collaborations with commercial and academic partners with expertise in the field of interest and through outsourcing activities to service providers.

Contact
ERGONEX Pharma GmbH
Ruetistr. 20
CH-9050 Appenzell
Switzerland
Phone: +41 71 788 4065
E-mail: info@ergonex.com
www.ergonex.com


'/>"/>
b3c newswire

Related biology news :

1. TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
2. InVivo and CEVEC pharmaceuticals sign license agreement regarding the use of human CAP-T Technology for production of recombinant proteins
3. Science survey ranks top biopharma employers
4. Jean-Pol Tassin wins the 2009 ECNP Neuropsychopharmacological Award
5. Researchers prolong the half-life of biopharmaceutical proteins
6. UA pharmacy research shows prescribers miss potentially dangerous drug pairs
7. 22nd Congress of the European College of Neuropsychopharmacology, Sept. 12-16, 2009, Turkey
8. 22nd Congress of the European College of Neuropsychopharmacology
9. Simulating pharmaceutical and personal care product transport
10. Tufts University professor receives IADR Pharmacology/Therapeutics/Toxicology Award
11. Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... focused on quality, regulatory and technical consulting, provides a free webinar ... presented on July 13, 2016 at 12pm CT at no charge. , Incomplete ...
(Date:6/22/2016)... SAN DIEGO , June 22, 2016 /PRNewswire/ ... partnership that will allow them to produce up ... (HiPSC) from one lot within one week. These ... their time laboriously preparing cells and spend more ... made possible through a proprietary, high-volume manufacturing process ...
Breaking Biology Technology: